Public Pharmaceutical Company: The Phase III clinical trial of the innovative drug RAY1225 injection for obesity/overweight, conducted by its holding subsidiary, has completed the enrollment of the first participant.

Zhongsheng Pharmaceutical announced that a type of innovative peptide drug RAY1225 injection developed by its controlling subsidiary Zhongsheng Ruichuang has recently completed the enrollment and dosing of the first participant in a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial on the safety and efficacy of obesity/overweight participants. RAY1225 injection is an innovative structural peptide drug developed by Zhongsheng Ruichuang with independent global intellectual property rights, with dual agonistic activity on GLP-1 receptors and GIP receptors. The phase III clinical trial has obtained ethics approval from the leading unit, and Zhongsheng Ruichuang actively organizes multiple research centers nationwide to participate and gradually launch the phase III clinical trial of RAY1225 injection.